The immunization scheme designed in Cuba consists of three doses of Abdala, which was developed by the Genetic Engineering and Biotechnology Center(CIGB) and has shown 92.28 percent of efficacy.
Meanwhile, the vaccine candidate produced by the Finlay Vaccines Institute (IFV) consists of two doses of Soberana 02, a scheme that reached 62 percent of that variable, and in the upcoming days the data will be updated with the addition of the third injection of Soberana Plus.
As part of the Strategy for the development of vaccine candidates against Covid-19, several forms of research are being carried out: clinical trials, intervention studies and health intervention.
The most recent statistics indicate that 2,774,473 Cubans have received at least one dose of the products, and the second dose has already been administered to 2,105,345 volunteers, MINSAP explained in its report. Cuba has other vaccine candidates against Covid-19: IFV’s Soberana 01; as well as CIGB’s Mambisa, a nasal formulation.